|Bid||496.96 x 1200|
|Ask||497.56 x 900|
|Day's Range||492.39 - 499.74|
|52 Week Range||430.24 - 589.32|
|Beta (3Y Monthly)||1.27|
|PE Ratio (TTM)||49.10|
|Earnings Date||Oct 16, 2019 - Oct 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||584.20|
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
On today's episode of Free Lunch here at Zacks, Associate Stock Strategist Ben Rains offers a quick global economic update. The episode also dives into Adidas (ADDYY), Lyft (LYFT), and Uber (UBER) earnings, and more...
Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.